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Abstract
Peripheral artery disease (PAD) is defined as atherosclerotic arterial occlusive disease of the lower extremities, man-
ifesting as intermittent claudication (IC, pain induced by walking) or critical limb ischaemia (CLI, rest pain or 
ulcerations). PAD guidelines recommend strict control of cardiovascular risk factors, and European guidelines on 
hypertension recommend a blood pressure (BP) target < 140/90 mm Hg also in PAD patients. As the pressure in the 
affected extremity might be of relevance for the prognosis concerning limb salvage in CLI, the traditional approach 
was to avoid beta-blockers and allow a slightly higher BP in CLI. Both theoretical considerations and observational 
data support aggressive BP lowering also in CLI; however, in the absence of randomized studies on BP lowering 
in this setting it cannot be definitely established that current recommendations on BP lowering apply also in CLI.
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Hypertension in peripheral arterial 
disease
Peripheral artery disease (PAD) is defined as ath-
erosclerotic arterial occlusive disease of the lower 
extremities. PAD can manifest as intermittent clau-
dication (IC, pain induced by walking) or critical 
limb ischaemia (CLI, rest pain or ulceration for more 
than 14 days) [1]. PAD affected 202 million people 
worldwide in 2010 [2, 3], and in a database of over 
9 million patients, PAD prevalence was 10.7% [4]. 
Furthermore, PAD patients have a high frequen-
cy of concomitant atherosclerotic disease, and risk 
factors for atherosclerosis such as arterial hyperten-
sion are common in this population [5, 6]. Major 
PAD guidelines issued by ACC/AHA [7] and TASC 
[1], recommend strict control of cardiovascular risk 
factors in this group of patients, and the current 
European guidelines on treatment of hypertension 
recommend a blood pressure (BP) target of less than 
140/90 mm Hg also in PAD patients [8].
Prior concerns on blood pressure treatment and 
beta-blocker use in IC patients have been offset by 
meta-analyses from the Cochrane Collaboration 
[9–11]. This work has confirmed that the benefits 
of treating hypertension in PAD patients are over-
whelming, whereas there is no clear evidence that any 
antihypertensive drug class confers specific benefits 
in relation to another [9–11]. The vast majority of 
patients in the studies in the above meta-analyses 
have, however, been included in studies with a diag-
nosis of IC. Patients with CLI represent about 1% 
of the total number of PAD patients [1], and as this 
condition is scientifically defined as chronic isch-
aemic rest pain, ulcers, or gangrene attributable to 
objectively proven arterial occlusive disease (ankle 
pressure of < 50–70 mm Hg, or toe pressure of 
< 30–50 mm Hg, or TCPO2 < 30–50 mm Hg) [1], 
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inclusion and follow-up of these patients in scientific 
studies of blood pressure lowering is complicated. 
Therefore, most review authors do not address this 
group specifically. 
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Furthermore, blood pressure might have other rele-
vance in CLI than as a risk factor for cardiovascular 
disease. As the pressure in the affected extremity 
might be of relevance for the prognosis concerning 
limb salvage, the traditional approach was to avoid 
beta-blockers and allow a slightly higher blood pres-
sure in this setting [12]. Additionally, the concept 
of increasing blood pressure and thereby increasing 
collateral circulation in an ischaemic extremity seems 
intuitionally appealing. Regional hyperperfusion via 
extracorporeal limb perfusion has been evaluated in 
CLI with promising results [13], and benefits of se-
quential pneumatic compression have been suggest-
ed in prevention of minor amputation, prolonging 
amputation-free survival, and improving rest pain in 
patients with non-reconstructable CLI [14]. 
Many factors would theoretically support a ben-
efit of aggressive blood pressure lowering also in 
CLI, however. High frequencies of concomitant cor-
onary heart disease [15, 16] congestive heart failure 
[16–18], and coronary valve disease [19] have been 
demonstrated in this group. In a necropsy study [16], 
92% of patients amputated because of CLI showed 
advanced coronary atherosclerosis. Five-year cardio-
vascular mortality in symptomatic PAD in different 
studies was recently estimated to 13% (CI 9–17%) 
by Sigvant et al. [20]. In CLI, this figure is higher 
— around 20% already after one year [21–23] and 
mainly caused by cardiac disease [21–23]. 
Blood pressure seems to be of relevance for this 
outcome. Increased preoperative pulse pressure [24] 
and uncontrolled hypertension [25] are associated 
with procedural complications and increased mor-
tality in patients after distal intervention for CLI. 
In other studies of primary revascularization in CLI 
patients, lack of beta-blocking therapy has been as-
sociated with increased risk of heart related adverse 
events [26, 27].
Conclusion
Although the above observational data from CLI 
patients supports recommendations on antihyper-
tensive treatment in CLI, it cannot be definitely 
established that current recommendations on anti-
hypertensive treatment apply also in this group in 
the absence of randomized studies on blood pressure 
lowering. Patients with CLI therefore need to be 
further studied by physicians with knowledge of and 
interest for treatment of arterial hypertension. As 
different relationships between blood pressure levels 
and tissue perfusion might apply in diabetic and 
non-diabetic patients with limb ischaemia [28, 29], 
these two groups should preferably be studied sep-
arately. 
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